Question 1

What are the specific gene changes in my leukemia, and do they qualify me for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Bleximenib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Bleximenib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests or monitoring will be required during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any restrictions on other treatments I can receive while in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) clinical trial (NCT04811560). Contact the study team or your healthcare provider for specific answers.

What this study is about